FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133507743> ?p ?o ?g. }

• W3133507743 endingPage "4041" @default.
• W3133507743 startingPage "4028" @default.
• W3133507743 abstract "Prostate cancer (PC) is one of the most common cancers in men. Although the overall prognosis is favorable, the management of metastatic castration-resistant prostate cancer (mCRPC) patients is challenging. Usually, mCRPC patients with progressive disease are considered for radioligand therapy (RLT) after exhaustion of other standard treatments. The prostate-specific membrane antigen (PSMA) labeled with Lutetium-177 ([177Lu]Lu-PSMA) has been widely used, showing favorable and successful results in reducing prostate-specific antigen (PSA) levels, increasing quality of life, and decreasing pain, in a multitude of studies. Nevertheless, approximately thirty percent of patients do not respond to [177Lu]Lu-PSMA RLT. Here, we only reviewed and reported the evaluated factors and their impact on survival or biochemical response to treatment to have an overview of the potentialprognostic parameters in [177Lu]Lu-PSMA RLT.Studies were retrieved by searching MEDLINE/PubMed and GoogleScholar. The search keywords were as follows: {(177Lu-PSMA) AND (radioligand) AND (prognosis) OR (predict)}. Studies discussing one or more factors which may be prognostic or predictive of response to [177Lu]Lu-PSMA RLT, that is PSA response and survival parameters, were included.Several demographic, histological, biochemical, and imaging factors have been assessed as predictive parameters for the response to thistreatment; however, the evaluated factors were diverse, and the results mostly were divergent, except for the PSA level reduction after treatment, which unanimously predicted prolonged survival.Several studies have investigated a multitude of factors to detect those predicting response to [177Lu]Lu-PSMA RLT. The results wereinconsistent regarding some factors, and some were evaluated in only a few studies. Future prospective randomized trials are required to detect theindependent prognostic factors, and to further determine the clinical and survival benefits of [177Lu]Lu-PSMA RLT." @default.
• W3133507743 created "2021-03-15" @default.
• W3133507743 creator A5006830341 @default.
• W3133507743 creator A5021061571 @default.
• W3133507743 creator A5031550729 @default.
• W3133507743 creator A5032276703 @default.
• W3133507743 creator A5051465639 @default.
• W3133507743 creator A5060184273 @default.
• W3133507743 creator A5066538954 @default.
• W3133507743 creator A5090375331 @default.
• W3133507743 date "2021-03-06" @default.
• W3133507743 modified "2023-10-17" @default.
• W3133507743 title "Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review" @default.
• W3133507743 cites W1544486867 @default.
• W3133507743 cites W1588197864 @default.
• W3133507743 cites W1788773500 @default.
• W3133507743 cites W1970345836 @default.
• W3133507743 cites W1994463565 @default.
• W3133507743 cites W1998345392 @default.
• W3133507743 cites W2059123939 @default.
• W3133507743 cites W2069422722 @default.
• W3133507743 cites W2092776013 @default.
• W3133507743 cites W2096220058 @default.
• W3133507743 cites W2155679349 @default.
• W3133507743 cites W2159771669 @default.
• W3133507743 cites W2165567204 @default.
• W3133507743 cites W2167869791 @default.
• W3133507743 cites W2175765437 @default.
• W3133507743 cites W2278392405 @default.
• W3133507743 cites W2296253991 @default.
• W3133507743 cites W2302508993 @default.
• W3133507743 cites W2303817381 @default.
• W3133507743 cites W2515351720 @default.
• W3133507743 cites W2516454849 @default.
• W3133507743 cites W2532226140 @default.
• W3133507743 cites W2562047649 @default.
• W3133507743 cites W2594458360 @default.
• W3133507743 cites W2612027160 @default.
• W3133507743 cites W2625296464 @default.
• W3133507743 cites W2743911086 @default.
• W3133507743 cites W2762824224 @default.
• W3133507743 cites W2763185726 @default.
• W3133507743 cites W2768513671 @default.
• W3133507743 cites W2780781461 @default.
• W3133507743 cites W2796597724 @default.
• W3133507743 cites W2799908504 @default.
• W3133507743 cites W2799931007 @default.
• W3133507743 cites W2875246115 @default.
• W3133507743 cites W2885022088 @default.
• W3133507743 cites W2886110678 @default.
• W3133507743 cites W2894392370 @default.
• W3133507743 cites W2895593497 @default.
• W3133507743 cites W2900829249 @default.
• W3133507743 cites W2901319364 @default.
• W3133507743 cites W2901578258 @default.
• W3133507743 cites W2904413085 @default.
• W3133507743 cites W2913256141 @default.
• W3133507743 cites W2914833937 @default.
• W3133507743 cites W2937409539 @default.
• W3133507743 cites W2937993567 @default.
• W3133507743 cites W2952358880 @default.
• W3133507743 cites W2969742213 @default.
• W3133507743 cites W2973957883 @default.
• W3133507743 cites W2977265552 @default.
• W3133507743 cites W2979393286 @default.
• W3133507743 cites W2990966824 @default.
• W3133507743 cites W3006239597 @default.
• W3133507743 cites W3008895328 @default.
• W3133507743 cites W3010388685 @default.
• W3133507743 cites W3012438007 @default.
• W3133507743 cites W3020273460 @default.
• W3133507743 cites W3021338686 @default.
• W3133507743 cites W3029981962 @default.
• W3133507743 cites W3040097601 @default.
• W3133507743 cites W3107314386 @default.
• W3133507743 cites W50627056 @default.
• W3133507743 doi "https://doi.org/10.1007/s00259-021-05237-y" @default.
• W3133507743 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8484081" @default.
• W3133507743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33677734" @default.
• W3133507743 hasPublicationYear "2021" @default.
• W3133507743 type Work @default.
• W3133507743 sameAs 3133507743 @default.
• W3133507743 citedByCount "23" @default.
• W3133507743 countsByYear W31335077432021 @default.
• W3133507743 countsByYear W31335077432022 @default.
• W3133507743 countsByYear W31335077432023 @default.
• W3133507743 crossrefType "journal-article" @default.
• W3133507743 hasAuthorship W3133507743A5006830341 @default.
• W3133507743 hasAuthorship W3133507743A5021061571 @default.
• W3133507743 hasAuthorship W3133507743A5031550729 @default.
• W3133507743 hasAuthorship W3133507743A5032276703 @default.
• W3133507743 hasAuthorship W3133507743A5051465639 @default.
• W3133507743 hasAuthorship W3133507743A5060184273 @default.
• W3133507743 hasAuthorship W3133507743A5066538954 @default.
• W3133507743 hasAuthorship W3133507743A5090375331 @default.
• W3133507743 hasBestOaLocation W31335077431 @default.
• W3133507743 hasConcept C121608353 @default.
• W3133507743 hasConcept C126322002 @default.

• next